USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Growth Opportunities in Sterile Injectable Outsourcing
Biologics Drive the Future Growth Potential of Sterile Injectable Outsourcing
08-Jun-2022
North America
Market Research
PD27-01-00-00-00
HC03548-NA-MT_26593
Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring
of biopharmaceutical products for COVID-19 and next-generation biologics has significantly increased the demand for aseptic fill-and-finish capacity and capabilities to meet the demand from various regions. All these factors have made sterile injectable drug product services outsourcing the most lucrative opportunity for contract development and manufacturing companies (CDMO)s. The sterile injectable outsourcing market is set to expand at a CAGR of 9.4%% from 2021 to 2026.
Accelerated project timeframes have prompted CDMOs to review their approach and consider strategies that support greater agility in fill-and-finish operations. The development and manufacturing of high-potency small molecules, less-soluble drugs, and targeted small molecules have allowed small-molecule CDMOs to showcase their capabilities and expertise to pharmaceutical partners. Similarly, biologic manufacturing requires advanced manufacturing/quality control technologies, equipment and skill sets. Biopharma companies and innovative biotech players are increasingly outsourcing process development and manufacturing to CDMOs that possess excellent technologies and equipment.
In this report, Frost & Sullivan offers:
• Insights through market forecasts
• Analysis by segment: small-molecule FDF and biologic drug product
• Market trends, drivers, and restraints
• CDMOs’ investment and expansion into injectable capacity
• Opportunities that stakeholders can pursue
Author: Surbhi Gupta
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Sterile Injectables Outsourcing
Growth Opportunities Fuel the Growth Pipeline Engine™
Key Takeaways
Scope of Analysis
Forecast Framework—CDMO
Forecast Methodology—Sterile Injectable Outsourcing
Forecast Assumptions
Key Growth Metrics
Growth Drivers
Growth Restraints
Revenue Forecast
Revenue Forecast by Product Type
Revenue Forecast Analysis
Therapeutic Area Overview
Therapeutic Area Overview (continued)
Supply Chain and the Evolving Role of Vendors
Recent Trends Driving Collaborations & Expansions
Recent Trends Driving Collaborations & Expansions (continued)
Capability Overview of Select CDMOs
CDMO Acquisitions and Sterile Injectable Capacity Expansion—US
CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)
CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)
CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe
CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe (continued)
CDMO Acquisitions and Sterile Injectable Capacity Expansion—APAC
Smartification of Injectable Delivery Device
Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities
Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities (continued)
Growth Opportunity 2: Strategic Partnerships that Provide Integrated Injectable Drug Product and Device Service
Growth Opportunity 2: Strategic Partnerships to Provide Integrated Injectable Drug Product and Device Service (continued)
Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics
Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics (continued)
List of Exhibits
Legal Disclaimer
List of Figures
- Sterile Injectable Outsourcing: Key Growth Metrics, Global, 2021
- Sterile Injectable Outsourcing: Growth Drivers, Global, 2022–2026
- Sterile Injectable Outsourcing: Growth Restraints, Global, 2022–2026
- Sterile Injectable Outsourcing: Revenue Forecast, Global, 2020–2026
- Sterile Injectable Outsourcing: Revenue Forecast by Product Type, Global, 2020–2026
- Sterile Injectable Outsourcing: Revenue Share by Therapeutic Area, Global, 2021 and 2026
- Sterile Injectable Outsourcing: Revenue Share by Technology Type, Global, 2021 and 2026
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
26 Oct 2026 | Global | Technology Research
Game-Changing Innovations Transforming Cardiovascular Care
The study analyzes game-changing technologies transforming cardiovascular care across diagnosis, image-guided intervention, functional assessment, clinical workflow, and longitudinal patient monitoring. The analysis covers five segments: diagnostic imaging and AI-enabled cardiac assessment; interven...
23 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Implantable and Diagnostic Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantable.The issue features advanced medical devices such as single-breath-hold radiotherapy system, transcatheter system f...
16 Oct 2026 | Global | Market Research
Public Sector Healthcare Cloud Market, North America and Europe, 2026
Public healthcare organizations across North America and Europe are using cloud technologies to support modernization efforts that extend beyond infrastructure replacement. Cloud is increasingly being adopted to improve interoperability, enable secure data sharing, support analytics and AI initiativ...
16 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Precision Therapeutics, AI-Enabled Discovery and Bioengineering, Regenerative Medicine, and Next-Generation Vaccine Platforms
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufactu...
15 Oct 2026 | Global | Frost Radar
Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026
The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As mo...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.